Abstract: Objective To explore the effect of recombinant bovine basic fibroblast growth factor on patients with hormone-dependent dermatitis, so as to find effective and safe therapeutic drugs for hormone-dependent dermatitis patients. Methods A total of 150 patients with hormone-dependent dermatitis who were treated in our hospital were selected from 2013 to 2018, and they were divided into observation group (n=81) and control group (n=69) according to different treatment methods. The patients in the observation group were treated with recombinant bovine basic fibroblast growth factor, while the patients in the control group were treated with carbomer. The clinical score, cuticular water content, percutaneous water loss, epidermal sebum content and adverse reactions were compared between the two groups. Results There were significant differences in clinical scores before treatment, 2 weeks and 4 weeks after treatment (all P<0.05), 2 weeks and 4 weeks after treatment, the clinical score of the observation group was significantly lower than that of the control group (all P<0.05). There were significant differences in percutaneous water loss and epidermal sebum content among the three groups before treatment, 2 weeks and 4 weeks after treatment (all P<0.05), there were significant differences in the cuticular water content before treatment, 2 weeks and 4 weeks after treatment in the observation group (P<0.05), but there was no significant difference in the cuticular water content before treatment, 2 weeks and 4 weeks after treatment in the control group (P>0.05). Two weeks after treatment, the percutaneous water loss in the observation group was significantly lower than that in the control group (P<0.05), and the epidermal sebum content in the observation group was significantly higher than that in the control group (P<0.05), but there was no significant difference in the cuticular water content between the two groups (P>0.05); 4 weeks after treatment, the cuticular water content and epidermal sebum content in the observation group were significantly higher than those in the control group (all P<0.05), and the percutaneous water loss in the observation group was significantly lower than that in the control group (P<0.05). No obvious adverse reactions occurred in the two groups. Conclusion Recombinant bovine basic fibroblast growth factor has a good effect in the treatment of hormone-dependent dermatitis, it can improve the clinical symptoms and signs, promote the repair of skin barrier, and has high safety.